Novartis to limit M&A spend to 5 of market value
Novartis to limit M&A spend to 5% of market value
Chief Vas Narasimhan looks to ‘drive more value for shareholders’ with focused deals
Original Article: Novartis to limit M&A spend to 5% of market value
More From BioPortfolio on "Novartis to limit M&A spend to 5% of market value"